Avanos Medical (AVNS) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price objectives for Avanos Medical's shares. Their AVNS share price forecasts range from $28.00 to $34.00. On average, they predict the company's share price to reach $30.25 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts.

Avanos Medical's stock was trading at $27.06 at the beginning of 2023. Since then, AVNS stock has decreased by 13.6% and is now trading at $23.39.
View the best growth stocks for 2023 here.

Avanos Medical saw a decrease in short interest in April. As of April 15th, there was short interest totaling 865,700 shares, a decrease of 7.4% from the March 31st total of 935,300 shares. Based on an average daily volume of 240,400 shares, the short-interest ratio is presently 3.6 days. Currently, 1.9% of the shares of the company are short sold.
View Avanos Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AVNS earnings forecast.

Avanos Medical, Inc. (NYSE:AVNS) released its earnings results on Wednesday, May, 3rd. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by $0.01. The company earned $191.70 million during the quarter, compared to analyst estimates of $195.20 million. Avanos Medical had a net margin of 5.34% and a trailing twelve-month return on equity of 6.11%. Avanos Medical's revenue for the quarter was down 2.9% on a year-over-year basis. During the same period last year, the company posted $0.26 earnings per share.

ETFs with the largest weight of Avanos Medical (NYSE:AVNS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Active Factor Small Cap ETF (AFSM), Royce Quant Small-Cap Quality Value ETF (SQLV), First Trust Small Cap Value AlphaDEX Fund (FYT), iShares S&P Small-Cap 600 Value ETF (IJS) and SPDR S&P 600 Small CapValue ETF (SLYV).

Avanos Medical updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of $1.60-$1.80 for the period, compared to the consensus estimate of $1.70. The company issued revenue guidance of -.

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.98%), Dimensional Fund Advisors LP (6.80%), State Street Corp (4.34%), Macquarie Group Ltd. (4.26%), Geode Capital Management LLC (1.88%) and Charles Schwab Investment Management Inc. (1.42%).
View institutional ownership trends.

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVNS stock can currently be purchased for approximately $23.39.

Avanos Medical (NYSE:AVNS) has a market capitalization of $1.09 billion and generates $820 million in revenue each year. The company earns $50.50 million in net income (profit) each year or $0.92 on an earnings per share basis.

The company employs 4,044 workers across the globe.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.